A previous study found an association between receptor density and response to daratumumab, reflecting an observed link between CD38 expression levels on patient MM cells and induced cell death by daratumumab via ADCC and CDC [28, 29]. The gene discussed is CD38; the disease is Miyoshi myopathy.